Grindeks
Corporate brand
UnclaimedGrindeks is a Latvian pharmaceutical company producing original medicines, generics, active pharmaceutical ingredients, and contract development and manufacturing services.
Last updated October 30, 2026
AI crawler reads
No AI crawler has read this profile yet.
Overview
Grindeks, formally JSC Grindeks and sometimes styled as Grindex, is an internationally operating pharmaceutical company headquartered in Riga, Latvia. It is one of the Baltic region's best-known drug manufacturers and operates across the development, production, registration, and supply of medicines and active pharmaceutical ingredients. The company's portfolio combines proprietary products, generic medicines, pharmaceutical substances, and manufacturing and development services for external partners. The business traces its institutional origins to 1946, when a predecessor known as the Vitamin and Hormones Plant was converted into an experimental pharmaceutical plant. In 1957, the plant became part of the newly established Organic Synthesis Institute, where it served as an industrial base for translating chemical and pharmaceutical research into commercial production. During the late 1950s and 1960s, the facility began producing medicines and chemical substances including fenilin, furazolidone, furadonin, and TioTEFA. It also developed capabilities in anticancer chemistry, tablet production, and finished-dose manufacturing. A major early international breakthrough came with Ftorafur, an anticancer medicine whose active ingredient was developed and manufactured at the plant. Cooperation agreements with Japanese pharmaceutical companies in the 1970s helped introduce the product to international markets. Another defining product is Mildronate, a cardioprotective medicine that became one of Grindeks' most recognizable brands and an important export product. The company's Soviet-era research environment produced numerous medicines and technologies, including a number of patented and original products. Following the restoration of Latvian independence, Grindeks was established as a Latvian state pharmaceutical research and manufacturing company in 1991. The name refers to Davids Hieronims Grindelis, a Latvian pharmacist, natural scientist, physician, and professor of chemistry. The company became a public joint-stock company in 1997, acquired a majority stake in Estonia's Tallinn Pharmaceutical Plant in 1998, and began trading its shares on the Riga Stock Exchange the same year. International manufacturing and quality credentials expanded in the late 1990s and 2000s, including Good Manufacturing Practice certification and ISO-based quality and environmental systems. Grindeks' main therapeutic focus is concentrated in cardiovascular medicines, central nervous system treatments, anticancer products, and diabetes-related medicines. Its finished-dose portfolio includes tablets, capsules, injectable solutions, ointments, gels, and syrups. The company also manufactures active pharmaceutical ingredients and offers development, analytical, regulatory, and production services through its group structure. These services cover projects from early development through GMP manufacturing and support market authorization procedures in the European Union and other international regions. The Grindeks Group includes the Latvian parent company and subsidiaries such as Kalceks in Latvia, HBM Pharma in Slovakia, Tallinn Pharmaceutical Plant in Estonia, and Namu apsaimniekošanas projekti in Latvia. The group maintains international offices and distribution activity in several markets across Eastern Europe, Central Asia, and neighboring regions. According to company information cited in the reference material, Grindeks exported products to more than 90 countries in 2021. The company has continued to invest in manufacturing capacity, including anticancer production, ursodeoxycholic acid active-ingredient production, finished-dose facilities, and ointment and gel manufacturing. In 2020 it announced plans for a new multifunctional plant. Grindeks also participates in contract development and manufacturing and has pursued research partnerships around new pharmaceutical substances. Its stated corporate-responsibility priorities include patient and employee health and safety, environmental protection, and ethical conduct. The company continues to invest in manufacturing capabilities, including anticancer production, ursodeoxycholic acid active-ingredient production, finished-dose facilities, and ointment and gel manufacturing. In 2020, it announced plans to build a new multifunctional plant. Grindeks is also involved in contract development and manufacturing and conducts research collaborations around new pharmaceutical substances. Its stated corporate responsibility priorities include patients and employees.
History
Grindeks developed from Latvia's postwar pharmaceutical research and manufacturing infrastructure. In 1946, the predecessor Vitamin and Hormones Plant was reorganized as an experimental plant for medicine production. Its role expanded in 1957 when it was incorporated into the Organic Synthesis Institute, becoming an industrial platform for applying chemical research and pharmaceutical innovation. During the late 1950s, the plant began manufacturing chemical and pharmaceutical products such as fenilin, furazolidone, furadonin, and TioTEFA. It established facilities for final dosage forms and tablet production and gradually developed particular expertise in organic synthesis and anticancer substances. In 1966, manufacturing technology for the active ingredient of Ftorafur was implemented. The plant produced a substantial number of medicines and related technologies during the 1960s, while anticancer research became an enduring part of its technical profile. The plant's international reach grew during the 1970s. Cooperation agreements with Japan's Iskra Industry and Taiho Pharmaceutical supported the supply of Ftorafur and helped establish the product internationally. During the same broad period, synthesis of Mildronate began. Mildronate later became Grindeks' best-known original product and a major export medicine. By the 1980s, the Organic Synthesis Institute and its experimental plant were credited in the reference material with creating dozens of new medicines, including patented and original products. After Latvia regained independence, the Latvian state pharmaceutical research and manufacturing company Grindeks was founded in 1991 on the basis of the experimental plant. The corporate name refers to Davids Hieronims Grindelis, a Latvian pharmacist, natural scientist, physician, and professor of chemistry. The enterprise was reorganized as a public joint-stock company in 1997. In 1998, Grindeks acquired a majority interest in Tallinn Pharmaceutical Plant and its shares began trading on the Riga Stock Exchange. The company pursued international quality and compliance recognition during the late 1990s and 2000s. It received a United Kingdom Good Manufacturing Practice certificate in 2000 for its tablet and capsule manufacturing operations and became the first Latvian pharmaceutical manufacturer to receive a Latvian State Agency of Medicines GMP certificate in 2003. It also introduced ISO 9001 quality-management principles, obtained environmental certification, and secured recognition related to the manufacture and control of oxytocin active ingredients. Grindeks joined the UN Global Compact and the chemical industry's Responsible Care program in 2002. Manufacturing expansion continued in the 2000s and 2010s. An analytical scale-up laboratory for active pharmaceutical ingredients opened in 2007, alongside a crystallization unit for the Mildronate substance. A new finished-dose plant opened in 2009. In 2011, Grindeks established an anticancer manufacturing unit and an ursodeoxycholic acid active-ingredient unit. The following year it opened an ointment and gel facility and agreed to acquire all shares of Slovak company HBM Pharma. Further occupational-health, quality, and regional certification followed in 2013. The modern Grindeks Group combines the Latvian parent with subsidiaries in Latvia, Estonia, and Slovakia. Its business includes original medicines, generics, active pharmaceutical ingredients, and contract development and manufacturing. Therapeutic priorities include cardiovascular, central nervous system, anticancer, and diabetes-related treatments. The company also supports regulatory submissions and pharmaceutical development for international customers. In 2020 it announced plans for a new multifunctional plant, while research linked to a cardioprotective substance known as GX-EG was cited as a possible future development program. Company information referenced in the source material states that the group exported to more than 90 countries in 2021.
- 2020
Multifunctional plant plans announced
[1]The group announced plans to build a new multifunctional pharmaceutical manufacturing plant.
- 2012
HBM Pharma acquisition agreed
[1]Grindeks agreed to acquire all shares of HBM Pharma in Slovakia and opened an ointment and gel manufacturing unit.
- 2011
Anticancer and UDCA production units established
[1]Grindeks established a new anticancer manufacturing unit and an ursodeoxycholic acid active-ingredient manufacturing unit.
- 2009
New finished-dose plant opened
[1]The company opened a finished-dose manufacturing plant designed to meet international pharmaceutical standards.
- 2007
API scale-up and Mildronate substance capacity expanded
[1]Grindeks opened an active-pharmaceutical-ingredient analytical scale-up laboratory and built a crystallization unit for Mildronate substance.
- 2000
United Kingdom GMP certification
[1]The company's tablet and capsule plant received a Good Manufacturing Practice certificate from the United Kingdom medicines regulator.
- 1998
Tallinn Pharmaceutical Plant investment and stock-market listing
[1]Grindeks acquired a majority shareholding in Tallinn Pharmaceutical Plant and its shares began trading on the Riga Stock Exchange.
- 1997
Public joint-stock company established
[1]Public Joint Stock Company Grindeks was established.
- 1991
Grindeks founded after Latvian independence
[1]The Latvian pharmaceutical research and manufacturing company Grindeks was established on the basis of the former experimental plant.
- 1972
Japanese cooperation supports Ftorafur exports
[1]The plant signed cooperation agreements with Japanese pharmaceutical companies to supply Ftorafur.
Products and positioning
A Baltic pharmaceutical manufacturer combining original medicines, generics, active pharmaceutical ingredients, international regulatory capabilities, and GMP-oriented development and manufacturing services. Its strongest historical associations are with cardiovascular, central nervous system, and anticancer products.
Original cardiovascular medicine
Mildronate
Mildronate is Grindeks' signature original product and one of the medicines most closely associated with the company. Its development is linked to the Soviet-era Organic Synthesis Institute and the experimental plant that preceded modern Grindeks. The product is positioned within the company's cardiovascular portfolio, and Grindeks has also developed substantial manufacturing capacity for its active pharmaceutical ingredient, including a crystallization unit commissioned in the 2000s.
Original anticancer medicine
Ftorafur
Ftorafur is an anticancer product whose active-ingredient manufacturing technology was implemented at the predecessor plant in the 1960s. International cooperation with Japanese pharmaceutical companies during the 1970s supported overseas supply and helped make the product one of the facility's earliest internationally recognized medicines. Ftorafur remains identified in the reference material as one of Grindeks' original products and a historically important export line.
Generic pharmaceuticals
Generic finished-dose medicines
Grindeks manufactures a broad portfolio of generic finished-dose medicines. The reference material describes more than 60 finished-dose products spanning solid dosage forms, injectable solutions, ointments, gels, and syrups. Therapeutic coverage is concentrated in cardiovascular, central nervous system, anticancer, hospital, and diabetes-related areas. Products are supplied across a large international network subject to market-specific registration requirements.
Pharmaceutical ingredients
Active pharmaceutical ingredients
Active pharmaceutical ingredients are a core part of Grindeks' manufacturing and contract-development business. The group produces substances for its own medicines and for external customers, supported by analytical scale-up, crystallization, specialized manufacturing units, and regulatory experience. The cited portfolio and facilities include Mildronate substance, oxytocin, ursodeoxycholic acid, and anticancer-related ingredients, although the precise current product list is not specified in the supplied material.
Contract development and manufacturing
Grindeks Group CDMO services
The Grindeks Group provides development, analytical, regulatory, and manufacturing services for active ingredients and finished pharmaceutical forms. Its stated capabilities cover early development through GMP production, controlled substances and investigational medicinal products, and assistance with European decentralized and mutual-recognition procedures. The group also reports experience supporting registrations in Australia, Canada, Southeast Asia, the Middle East, and CIS markets.
Brand decisions
2020
Plan for a new multifunctional manufacturing plantStrategyBackground
The group announced further investment in its production infrastructure as it expanded its pharmaceutical and active-ingredient activities.
Action taken
Grindeks announced plans to build a new multifunctional plant.
2012
Agreement to acquire HBM PharmaM&ABackground
Grindeks pursued further international expansion and additional pharmaceutical manufacturing capabilities in Central Europe.
Action taken
The company agreed to acquire 100 percent of the shares of HBM Pharma in Slovakia.
Aftermath
HBM Pharma became one of the subsidiaries identified within Grindeks Group.
2009
Expansion of finished-dose manufacturingStrategyBackground
The company sought to increase production capacity and align finished-dose operations with international pharmaceutical standards.
Action taken
Grindeks opened a new finished-dose pharmaceutical manufacturing plant.
Aftermath
The facility expanded the group's capacity for tablets, capsules, injectable products, and other finished forms.
1998
Acquisition of a majority stake in Tallinn Pharmaceutical PlantM&ABackground
Following its conversion into a public joint-stock company, Grindeks expanded its regional manufacturing footprint through an investment in Estonia.
Action taken
Grindeks acquired a majority shareholding in Tallinn Pharmaceutical Plant.
Aftermath
Tallinn Pharmaceutical Plant became part of the group's Baltic operating structure.
Sources2 sources
Cite this profile: Cite the canonical profile. /brand-wiki/grindeks · Editorial policy · How profiles are compiled